Showing 5051-5060 of 5771 results for "".
- Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the US, the First and Only FDA-Approved Trifocal Lenshttps://modernod.com/news/alcon-introduces-acrysof-iq-panoptix-trifocal-iol-in-the-us-the-first-and-only-fda-approved-trifocal-lens/2476827/Alcon announced the FDA approval and the initial commercial launch of the AcrySof IQ PanOptix Trifocal IOL, the first and only trifocal lens approved in the United States. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate, and distance vision while reducing
- Iconic Therapeutics Signs Ophthalmology Option Agreement With Novartishttps://modernod.com/news/iconic-therapeutics-signs-ophthalmology-option-agreement-with-novartis/2476818/Iconic Therapeutics announced that the company has signed an agreement with Novartis in which Novartis will have an option on Iconic’s ophthalmology program, now in preclinical development. Novartis made an upfront payment and an equity investment in Iconic. The details of investment were not dis
- New World Medical Launches Ahmed ClearPath Glaucoma Drainage Devicehttps://modernod.com/news/new-world-medical-launches-ahmed-clearpath-glaucoma-drainage-device/2476814/New World Medical announced the launch of the Ahmed ClearPath glaucoma drainage device, which is available in two sizes, 350 mm2 and 250 mm.2 A unique feature of the Ahmed ClearPath implant is a flexible plate with a contour that closely conforms to the curvature of the eye
- Clearside Biomedical Provides New Drug Application Update for Xiperehttps://modernod.com/news/clearside-biomedical-provides-new-drug-application-update-for-xipere/2476815/Clearside Biomedical announced an update regarding the company’s new drug application (NDA) for Xipere (triamcinolone acetonide suprachoroidal injectable suspension) with the FDA. In a meeting this week, the FDA’s Office of Pharmaceutical Quality (OPQ) reque
- Orbis Celebrates New Data Showing a 91% Reduction in Populations at Risk of Blinding Trachoma in Endemic Areashttps://modernod.com/news/orbis-celebrates-new-data-showing-a-91-reduction-in-populations-at-risk-of-blinding-trachoma-in-endemic-areas/2479544/The World Health Organization (WHO) announced new data that revealed the number of people at risk for trachoma had fallen from 1.5 billion in 2002 to 142 million in 2019—a 91% reduction, according to Orbis International. The report was released at the annual meeting of the WHO Alliance fo
- Nidek Launches the Mirante Scanning Laser Ophthalmoscopehttps://modernod.com/news/nidek-launches-the-mirante-scanning-laser-ophthalmoscope/2479546/Nidek has announced the launch of the Mirante Scanning Laser Ophthalmoscope. The Mirante is a multimodal fundus imaging platform that combines high definition SLO and OCT with ultra widefield imaging. The multimodal p
- Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Wet AMD and DMEhttps://modernod.com/news/aerie-pharmaceuticals-initiates-first-in-human-clinical-trial-of-ar-13503-sustained-release-intravitreal-implant-in-patients-with-wet-amd-and-dme/2476812/Aerie Pharmaceuticals announced the commencement of patient dosing in a first-in-human clinical trial of AR-13503 Sustained Release (SR) implant in patients with neovascular age-related macular degeneration (AMD) or diabetic macular edema (DME). This multi-arm, 24-week study (AR-13503-CS20
- Alcon to Launch Precision1 Daily Disposable Contact Lenseshttps://modernod.com/news/alcon-to-launch-precision1-daily-disposable-contact-lenses/2476810/Alcon announced plans to launch Precision1 daily disposable, silicone hydrogel (SiHy) contact lenses in the United States. Precision1 features Alcon’s proprietary Smartsurface technology—a permanent, micro-thin, high-performance layer of moisture at the lens surface that helps support a stable te
- Maui Jim and VSP Global Expand Relationship to Include Maui Jim Inside the VSP Formularyhttps://modernod.com/news/maui-jim-and-vsp-global-expand-relationship-to-include-maui-jim-inside-the-vsp-formulary/2479547/Maui Jim, the sunglass and eyewear supplier, announced “a significant step forward in its ongoing relationship with VSP Global,” reporting that Maui Jim will officially be available within the VSP formulary and will be included in the VSP contract lab network, according to a VisionMon
- AcuFocus Completes Study Enrollment for U.S. IDE Clinical Trial of IC-8 Lenshttps://modernod.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/AcuFocus announced that it has completed enrollment in its pivotal US investigational device exemption (IDE) study of the company’s IC-8 small aperture IOL. FDA granted approval of the company’s IDE on November 21, 2018, and the Investigational Review Board approved the study just 5